Company Overview and News

 
VGZ / Vista Gold Corp. DEFA14A

2018-03-16 sec.gov
current notice and access SCHEDULE 14A INFORMATION
Upvote Downvote

 
VGZ / Vista Gold Corp. DEF 14A

2018-03-16 sec.gov
current circular SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
VGZ / Vista Gold Corp. DEFA14A

2018-03-16 sec.gov
current annual return card SCHEDULE 14A INFORMATION
Upvote Downvote

 
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-03-12 sec.gov
Q4 17 031218 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

1
New Strong Sell Stocks for March 12th

2018-03-12 zacks
Voya Financial, Inc. (VOYA - Free Report) is the owner and operator of a retirement investment and insurance company. The Zacks Consensus Estimate for its current year earnings has been revised 0.5% downward over the last 30 days.
Upvote Downvote

 
Vista Gold's (VGZ) CEO Fred Earnest on Q4 2017 Results - Earnings Call Transcript

2018-03-10 seekingalpha
Good day, ladies and gentlemen. Welcome to Vista Gold’s 2017 Financial Results and 2018 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Today is Friday, March 9, 2017. It is now my pleasure to introduce Vista’s President and CEO and your host, Mr. Fred Earnest. Please go ahead, Mr. Earnest.
Upvote Downvote

 
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-03-08 sec.gov
Technical report 030718 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
VGZ / Vista Gold Corp. 10-K (Annual Report)

2018-03-06 sec.gov
vgz_Current folio_10K Table of Contents
Upvote Downvote

 
VGZ / Vista Gold Corp. / SUN VALLEY GOLD LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 7)*     Vista Gold Corp. (Name of Issuer)     Common Shares without par value (Title of Class of Securities)     927926303 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 13d-1(c)   [_] Ru
Upvote Downvote

1
VGZ / Vista Gold Corp. / SUN VALLEY GOLD LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 7)*     Vista Gold Corp. (Name of Issuer)     Common Shares without par value (Title of Class of Securities)     927926303 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 13d-1(c)   [_] Ru
Upvote Downvote

 
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-01-29 sec.gov
PFS 012918 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  _________________ FORM 8-K  CURRENT REPORT  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 24, 2018 (Date of earliest event reported) VISTA GOLD CORP. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada (State or Other Jurisdiction of Incorporation) 1-9025 (Commission File Number) Not Applicable (IRS Employer Identification No.
Upvote Downvote

 
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-01-25 sec.gov
EPBC 012518 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  _________________ FORM 8-K  CURRENT REPORT  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 22, 2018 (Date of earliest event reported) VISTA GOLD CORP. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada (State or Other Jurisdiction of Incorporation) 1-9025 (Commission File Number) Not Applicable (IRS Employer Identification No.
Upvote Downvote

 
VGZ / Vista Gold Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-16 fintel.io
Vista Gold Corp. (AMEX:VGZ) has 28 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28,963,976 shares. Largest shareholders include Sun Valley Gold Llc, Global Strategic Management Inc, Loews Corp, California Public Employees Retirement System, Wells Fargo & Company/mn, Morgan Stanley, Goldman Sachs Group Inc, Sprott Inc.
Upvote Downvote

 
VGZ / Vista Gold Corp. / GLOBAL STRATEGIC MANAGEMENT INC - ANNUAL BENEFICIAL OWNERSHIP FILING FOR VISTA GOLD (Passive Investment)

2018-01-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 5 Vista Gold Corporation ----------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value -------------------------------------------------------
Upvote Downvote

 
VGZ / Vista Gold Corp. / GLOBAL STRATEGIC MANAGEMENT INC - ANNUAL BENEFICIAL OWNERSHIP FILING FOR VISTA GOLD (Passive Investment)

2018-01-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 5 Vista Gold Corporation ----------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value -------------------------------------------------------
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 927926303